Login / Signup

Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.

Patrick C GedeonCosette D ChampionKristen E RhodinKarolina WoronieckaHanna R KemenyAlexa N BramallJoshua D BernstockBryan D ChoiJohn H Sampson
Published in: Expert review of clinical pharmacology (2020)
Evidence indicates that while clinical success of checkpoint blockade for the treatment of GBM has been limited to date, through improved preclinical models, optimization in the context of standard of care therapies, assay standardization and harmonization, and combinatorial approaches which may include novel targets for checkpoint blockade, checkpoint inhibitor immunotherapy may yield a safe and effective therapeutic option for the treatment of GBM.
Keyphrases
  • dna damage
  • cell cycle
  • healthcare
  • palliative care
  • stem cells
  • combination therapy
  • cell proliferation
  • oxidative stress
  • quality improvement
  • pain management